A lack of reliable, high-throughput platforms to identify safe therapeutic candidates slows drug discovery efforts for chronic intestinal diseases. To solve this problem, researchers have developed human stem cell-based platforms to recreate the intestinal epithelium. Such intestine-on-a-chip strategies create physiological representatives of the human gut, allowing researchers to reliably characterize gastrointestinal disease mechanisms and screen for safe, effective therapeutic candidates. In this webinar, brought to you by Altis, Bill Thelin, PhD, Chief Scientific Officer will describe how RepliGut® provides an ideal intestine-on-a-chip platform to support early-stage drug development.
Topics to be covered
Viewers of the webinar will have an opportunity to apply for a research project, value up to $10k
Bill Thelin, PhD, Chief Scientific Officer